National Institute on Aging - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH69716D
- Pages: 61
- September 2018
- Total Views:1138
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
National Institute on Aging (NIA), a subsidiary of National Institutes of Health is a healthcare institute that offers health and aging care services. The institute conducts research on aging through researchers and the international community of scientists. Its services comprise research, extramural program, research funding, training, intramural program, basic, clinical research and health information. NIA operates various departments such as geriatrics and clinical gerontology, neurosciences, extramural activities, scientific review, aging biology, behavioral and social research, among others. The institute also offers consumer-oriented information on topics related to older people and their families. NIA is headquartered in Bethesda, Maryland, the US.
National Institute on Aging-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Aging, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Aging, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
National Institute on Aging, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 11
Licensing Agreements 12
Peptron Enters into Licensing Agreement with National Institute on Aging 12
Elixirgen Enters into License Agreement with National Institute on Aging 13
National Institute on Aging-Key Competitors 14
National Institute on Aging-Key Employees 15
National Institute on Aging-Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Jul 30, 2018: Advancing the Search for Antibodies to Treat Alzheimer's Disease 17
Jul 25, 2018: Protein affected by rare Parkinson's mutation may lurk behind many cases of the disease 18
Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 20
Jul 09, 2018: Senolytic drugs reverse damage caused by senescent cells in mice 21
Jun 26, 2018: New tests aim to support improvements in care for those dealing with delirium 22
Jun 21, 2018: Unusually High Levels of Herpesviruses Found in the Alzheimer's Disease Brain, Mount Sinai Researchers Report 23
Jun 07, 2018: Genes linked to Alzheimer's contribute to damage in different ways 25
May 31, 2018: City of Hope receives USD 2 million grant to promote critical research on aging and cancer 26
May 29, 2018: Tgen, Northwestern University Study Of 'Superagers' Offers Genetic Clues To Their Cognitive Performance 27
May 10, 2018: GW Participates in Study that Supports Revised AHA Hypertension Guidelines 28
Apr 17, 2018: Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer's Disease 29
Apr 10, 2018: New biological research framework for Alzheimer's to spur discovery 30
Feb 06, 2018: Compound prevents neurological damage, shows cognitive benefits in mouse model of Alzheimer's disease 32
Jan 09, 2018: Researchers Receive USD 2.8 Million to Repurpose FDA-approved Drugs to Treat Alzheimer's Disease 33
Nov 16, 2017: Researchers identify first brain training exercise positively linked to dementia prevention 35
Nov 07, 2017: OMRF researcher receives Alzheimer's grant 36
Nov 06, 2017: Higher brain glucose levels may mean more severe Alzheimer's 37
Nov 02, 2017: Study explores nicotine patch to treat mild cognitive impairment 38
Oct 27, 2017: Applied BioMath awarded grant by National Institute on Aging of the NIH for the development of a systems pharmacology model in Alzheimer's Disease and Dementia 40
Oct 26, 2017: Study shows brain structures make some people resilient to Alzheimer's disease 41
Oct 17, 2017: Cleveland Clinic Earns NIH Grant to Study Benefits of Exercise in People at Risk for Alzheimer's Disease 43
Oct 10, 2017: UC Irvine: Effort to Create Mouse That More Closely Mirrors Human Alzheimer's Wins Federal Grant 44
Oct 09, 2017: IU awarded USD 7.6 million grant to establish groundbreaking study of early-onset Alzheimer's disease 45
Oct 02, 2017: Cleveland Clinic, The MetroHealth System Receive Grant to Enhance Heart Disease Risk Calculators 46
Sep 20, 2017: Rethink on beta blockers for heart attack survivors who take their other heart medication 47
Sep 18, 2017: New USD 5.4M grant funds JAX studies of 'cognitive resilience' to Alzheimer's disease 48
Sep 15, 2017: Afraxis Wins NIH Grant to Advance Synaptic Profiling Platform for CNS Drug Discovery 49
Sep 07, 2017: Oligomerix Awarded National Institute on Aging SBIR Grant for Development of Alzheimer's Disease Specific Biomarker 50
Aug 14, 2017: Brain Scan Study Adds to Evidence That Lower Brain Serotonin Levels are Linked to Dementia 51
May 14, 2017: New USD 2.7M Federal Grant Awarded To Jax Alzheimer's Researcher 53
May 14, 2017: New USD 3.2M federal grant awarded to JAX Alzheimers researcher 54
Apr 13, 2017: Researcher Receives Five-Year Grant From the National Institute on Aging at the National Institutes of Health 55
Product News 57
Jul 09, 2018: Senolytics Improve Health, Extend life: Preclinical research findings 57
Other Significant Developments 58
Sep 16, 2018: Daily low-dose aspirin found to have no effect on healthy life span in older people 58
Jul 04, 2018: Pathway of Alzheimer's degeneration discovered 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
List Of Figure
List of Figures
National Institute on Aging, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Aging, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
National Institute on Aging, Pharmaceuticals & Healthcare, Key Facts 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Aging, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Aging, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Aging, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 11
Peptron Enters into Licensing Agreement with National Institute on Aging 12
Elixirgen Enters into License Agreement with National Institute on Aging 13
National Institute on Aging, Key Competitors 14
National Institute on Aging, Key Employees 15
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
National Institute on Aging, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
National Institute on Aging (NIA), a subsidiary of National Institutes of Health is a healthcare institute that offers health and aging care services. The institute conducts research on aging through researchers and the international community of scientists. Its services comprise research, extramural program, research funding, training, intramural program, basic, clinical research and health information. NIA operates various departments such as geriatrics and clinical gerontology, neurosciences, extramural activities, scientific review, aging biology, behavioral and social research, among others. The institute also offers consumer-oriented information on topics related to older people and their families. NIA is headquartered in Bethesda, Maryland, the US.
National Institute on Aging-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Aging, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Aging, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
National Institute on Aging, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 11
Licensing Agreements 12
Peptron Enters into Licensing Agreement with National Institute on Aging 12
Elixirgen Enters into License Agreement with National Institute on Aging 13
National Institute on Aging-Key Competitors 14
National Institute on Aging-Key Employees 15
National Institute on Aging-Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Jul 30, 2018: Advancing the Search for Antibodies to Treat Alzheimer's Disease 17
Jul 25, 2018: Protein affected by rare Parkinson's mutation may lurk behind many cases of the disease 18
Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 20
Jul 09, 2018: Senolytic drugs reverse damage caused by senescent cells in mice 21
Jun 26, 2018: New tests aim to support improvements in care for those dealing with delirium 22
Jun 21, 2018: Unusually High Levels of Herpesviruses Found in the Alzheimer's Disease Brain, Mount Sinai Researchers Report 23
Jun 07, 2018: Genes linked to Alzheimer's contribute to damage in different ways 25
May 31, 2018: City of Hope receives USD 2 million grant to promote critical research on aging and cancer 26
May 29, 2018: Tgen, Northwestern University Study Of 'Superagers' Offers Genetic Clues To Their Cognitive Performance 27
May 10, 2018: GW Participates in Study that Supports Revised AHA Hypertension Guidelines 28
Apr 17, 2018: Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer's Disease 29
Apr 10, 2018: New biological research framework for Alzheimer's to spur discovery 30
Feb 06, 2018: Compound prevents neurological damage, shows cognitive benefits in mouse model of Alzheimer's disease 32
Jan 09, 2018: Researchers Receive USD 2.8 Million to Repurpose FDA-approved Drugs to Treat Alzheimer's Disease 33
Nov 16, 2017: Researchers identify first brain training exercise positively linked to dementia prevention 35
Nov 07, 2017: OMRF researcher receives Alzheimer's grant 36
Nov 06, 2017: Higher brain glucose levels may mean more severe Alzheimer's 37
Nov 02, 2017: Study explores nicotine patch to treat mild cognitive impairment 38
Oct 27, 2017: Applied BioMath awarded grant by National Institute on Aging of the NIH for the development of a systems pharmacology model in Alzheimer's Disease and Dementia 40
Oct 26, 2017: Study shows brain structures make some people resilient to Alzheimer's disease 41
Oct 17, 2017: Cleveland Clinic Earns NIH Grant to Study Benefits of Exercise in People at Risk for Alzheimer's Disease 43
Oct 10, 2017: UC Irvine: Effort to Create Mouse That More Closely Mirrors Human Alzheimer's Wins Federal Grant 44
Oct 09, 2017: IU awarded USD 7.6 million grant to establish groundbreaking study of early-onset Alzheimer's disease 45
Oct 02, 2017: Cleveland Clinic, The MetroHealth System Receive Grant to Enhance Heart Disease Risk Calculators 46
Sep 20, 2017: Rethink on beta blockers for heart attack survivors who take their other heart medication 47
Sep 18, 2017: New USD 5.4M grant funds JAX studies of 'cognitive resilience' to Alzheimer's disease 48
Sep 15, 2017: Afraxis Wins NIH Grant to Advance Synaptic Profiling Platform for CNS Drug Discovery 49
Sep 07, 2017: Oligomerix Awarded National Institute on Aging SBIR Grant for Development of Alzheimer's Disease Specific Biomarker 50
Aug 14, 2017: Brain Scan Study Adds to Evidence That Lower Brain Serotonin Levels are Linked to Dementia 51
May 14, 2017: New USD 2.7M Federal Grant Awarded To Jax Alzheimer's Researcher 53
May 14, 2017: New USD 3.2M federal grant awarded to JAX Alzheimers researcher 54
Apr 13, 2017: Researcher Receives Five-Year Grant From the National Institute on Aging at the National Institutes of Health 55
Product News 57
Jul 09, 2018: Senolytics Improve Health, Extend life: Preclinical research findings 57
Other Significant Developments 58
Sep 16, 2018: Daily low-dose aspirin found to have no effect on healthy life span in older people 58
Jul 04, 2018: Pathway of Alzheimer's degeneration discovered 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
List Of Figure
List of Figures
National Institute on Aging, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Aging, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
National Institute on Aging, Pharmaceuticals & Healthcare, Key Facts 2
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
National Institute on Aging, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
National Institute on Aging, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
National Institute on Aging, Deals By Therapy Area, 2012 to YTD 2018 9
National Institute on Aging, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Human Metabolome Technologies Enters into Agreement with National Institute on Aging 11
Peptron Enters into Licensing Agreement with National Institute on Aging 12
Elixirgen Enters into License Agreement with National Institute on Aging 13
National Institute on Aging, Key Competitors 14
National Institute on Aging, Key Employees 15
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
National Institute on Aging, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020